What is B. Riley's Estimate for WVE Q1 Earnings?

Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Investment analysts at B. Riley issued their Q1 2025 EPS estimates for shares of Wave Life Sciences in a research note issued on Wednesday, November 13th. B. Riley analyst M. El-Saadi anticipates that the company will post earnings per share of ($0.25) for the quarter. B. Riley has a "Buy" rating and a $22.00 price objective on the stock. The consensus estimate for Wave Life Sciences' current full-year earnings is ($1.06) per share. B. Riley also issued estimates for Wave Life Sciences' Q2 2025 earnings at ($0.24) EPS.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.19). Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. The firm had revenue of ($7.68) million during the quarter, compared to the consensus estimate of $15.45 million.

A number of other brokerages also recently weighed in on WVE. StockNews.com downgraded shares of Wave Life Sciences from a "hold" rating to a "sell" rating in a research report on Wednesday. HC Wainwright restated a "buy" rating and issued a $22.00 price target on shares of Wave Life Sciences in a research note on Wednesday. Leerink Partners boosted their price objective on Wave Life Sciences from $20.00 to $22.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 16th. Royal Bank of Canada raised their target price on Wave Life Sciences from $7.00 to $15.00 and gave the company a "sector perform" rating in a research report on Monday, October 21st. Finally, JPMorgan Chase & Co. lifted their target price on Wave Life Sciences from $13.00 to $17.00 and gave the company an "overweight" rating in a research note on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $21.89.

Wave Life Sciences Stock Performance

Shares of NASDAQ WVE traded down $1.33 during trading on Friday, reaching $13.67. The stock had a trading volume of 1,432,809 shares, compared to its average volume of 1,114,433. The stock has a market cap of $1.71 billion, a PE ratio of -12.32 and a beta of -1.20. Wave Life Sciences has a one year low of $3.50 and a one year high of $16.74. The firm's 50 day moving average price is $10.76 and its two-hundred day moving average price is $7.52.

Institutional Investors Weigh In On Wave Life Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC increased its stake in shares of Wave Life Sciences by 171.1% in the third quarter. Barclays PLC now owns 159,241 shares of the company's stock worth $1,307,000 after acquiring an additional 100,498 shares during the last quarter. Orion Portfolio Solutions LLC purchased a new position in Wave Life Sciences in the third quarter valued at about $123,000. XTX Topco Ltd acquired a new position in Wave Life Sciences in the 3rd quarter worth about $126,000. Jane Street Group LLC raised its stake in shares of Wave Life Sciences by 33.3% during the 3rd quarter. Jane Street Group LLC now owns 142,014 shares of the company's stock worth $1,165,000 after purchasing an additional 35,472 shares in the last quarter. Finally, Weiss Asset Management LP bought a new stake in shares of Wave Life Sciences in the 3rd quarter valued at approximately $164,000. Hedge funds and other institutional investors own 89.73% of the company's stock.

Insider Transactions at Wave Life Sciences

In other news, CEO Paul Bolno sold 51,234 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $14.32, for a total value of $733,670.88. Following the completion of the sale, the chief executive officer now owns 217,351 shares in the company, valued at $3,112,466.32. This represents a 19.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Plc Gsk acquired 2,791,930 shares of the firm's stock in a transaction on Friday, September 27th. The shares were acquired at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the transaction, the insider now directly owns 16,775,691 shares in the company, valued at approximately $134,205,528. This trade represents a 19.97 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 452,056 shares of company stock valued at $5,955,438. Corporate insiders own 29.10% of the company's stock.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.